Latest news
GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China - GSKGSK · Tue, 28 Jul 2026 07:00:00 GMTGSK’s licensor Hansoh Pharma announces positive new Ris-Rez data - The Pharma LetterThe Pharma Letter · Tue, 28 Jul 2026 07:00:00 GMTGSK Licensor's Late-Stage China Study for Risvutatug Rezetecan in Bone Cancer Meets Primary Endpoint - marketscreener.commarketscreener.com · Tue, 28 Jul 2026 07:00:00 GMT